Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) but lowers the price target from $51 to $50.
May 10, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush maintains an Outperform rating on Xenon Pharmaceuticals but lowers the price target from $51 to $50.
The adjustment in price target by a prominent analyst like Laura Chico could have a mixed impact. While maintaining an Outperform rating signals continued confidence in the company's prospects, the reduction in price target might raise concerns among investors about the near-term valuation upside, potentially leading to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100